inclusion criteria: 1. participants of 18 years of age or older 2. participants who have a positive sars-cov-2 test result, and have sample collection for first positive sars-cov-2 viral infection determination ≤5 days prior to randomization 3. participants who have one or more mild or moderate covid-19 symptoms as follows and have a covid-19 related symptom score ≥3 4. participants with the onset of symptoms of covid-19 ≤5 days prior to randomization 5. participants who satisfy one or more than one of the following high risks for progression to severe covid-19, including death: 6. participants who must agree to adhere to contraception restrictions 7. participants who understand and agree to comply with planned study procedures 8. participants can give written informed consent approved by the ethical review board governing the site and comply with the requirements and restrictions listed in the informed consent form (icf) and in this protocol

inclusion criteria: 1. participants of 18 years of age or older 2. participants who have a positive sars-cov-2 test result, and have sample collection for first positive sars-cov-2 viral infection determination ≤5 days prior to randomization 3. participants who have one or more mild or moderate covid-19 symptoms as follows and have a covid-19 related symptom score ≥3 4. participants with the onset of symptoms of covid-19 ≤5 days prior to randomization 5. participants who satisfy one or more than one of the following high risks for progression to severe covid-19, including death: 6. participants who must agree to adhere to contraception restrictions 7. participants who understand and agree to comply with planned study procedures 8. participants can give written informed consent approved by the ethical review board governing the site and comply with the requirements and restrictions listed in the informed consent form (icf) and in this protocol

inclusion criteria: participants of 18 years of age or older participants who have a positive sars-cov-2 test result, and have sample collection for first positive sars-cov-2 viral infection determination ≤5 days prior to randomization participants who have one or more mild or moderate covid-19 symptoms as follows and have a covid-19 related symptom score ≥3 participants with the onset of symptoms of covid-19 ≤5 days prior to randomization participants who satisfy one or more than one of the following high risks for progression to severe covid-19, including death: participants who must agree to adhere to contraception restrictions participants who understand and agree to comply with planned study procedures participants can give written informed consent approved by the ethical review board governing the site and comply with the requirements and restrictions listed in the informed consent form (icf) and in this protocol

inclusion criteria: participants of 18 years of age or older participants who have a positive sars-cov-2 test result, and have sample collection for first positive sars-cov-2 viral infection determination ≤5 days prior to randomization participants who have one or more mild or moderate covid-19 symptoms as follows and have a covid-19 related symptom score ≥3 participants with the onset of symptoms of covid-19 ≤5 days prior to randomization participants who satisfy one or more than one of the following high risks for progression to severe covid-19, including death: participants who must agree to adhere to contraception restrictions participants who understand and agree to comply with planned study procedures participants can give written informed consent approved by the ethical review board governing the site and comply with the requirements and restrictions listed in the informed consent form (icf) and in this protocol

inclusion criteria: participants who have a positive sars-cov-2 test result participants who have one or more mild or moderate covid-19 symptoms, such as fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, shortness of breath with exertion participants who have sample collection for first positive sars-cov-2 viral infection determination and the onset of symptoms of covid-19 ≤5 days prior to randomization participants who satisfy one or more than one of the following high risks for progression to severe covid-19, including death: participants who must agree to adhere to contraception restrictions participants who understand and agree to comply with planned study procedures participants or legally authorized representatives can give written informed consent approved by the ethical review board governing the site capable of giving signed informed consent as described in appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol

inclusion criteria: participants who have a positive sars-cov-2 test result participants who have one or more mild or moderate covid-19 symptoms, such as fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, shortness of breath with exertion participants who have sample collection for first positive sars-cov-2 viral infection determination and the onset of symptoms of covid-19 ≤5 days prior to randomization participants who satisfy one or more than one of the following high risks for progression to severe covid-19, including death: participants who must agree to adhere to contraception restrictions participants who understand and agree to comply with planned study procedures participants or legally authorized representatives can give written informed consent approved by the ethical review board governing the site capable of giving signed informed consent as described in appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol